November 21, 2023 News by Steve Bryson, PhD Vumerity reduces relapses, lesions over 2 years: EVOLVE-MS-1 study Nearly two years of treatment with Vumerity (diroximel fumarate) significantly reduced relapse rates by more than 80% in people with relapsing-remitting multiple sclerosis (RRMS), according to the final published details of the EVOLVE-MS-1 clinical trial. MRI scans also showed the number of active inflammatory lesions and new…
October 6, 2023 News by Marisa Wexler, MS Progression without relapses drives most disability worsening in MS Most disability worsening events happen independent of relapse activity across all types of multiple sclerosis (MS), including clinically isolated syndrome (CIS) and early relapsing-remitting MS (RRMS), a new study reports. The findings challenge the idea that relapses are the main driver of disability worsening in early relapsing…
September 12, 2023 News by Steve Bryson, PhD No greater risk of hospitalization found after vaccines in MS in study People with multiple sclerosis (MS) who receive vaccines against influenza ā commonly known as flu shots ā as well as diphtheria, polio, pneumoccocus, and multiple other pathogens are not significantly more likely to be hospitalized due to a disease relapse, according to a new study in France. Similar…
August 15, 2023 News by Marisa Wexler, MS Diet shows no association with relapses, disability progression A higher quality diet is associated with reductions in certain types of brain lesions in multiple sclerosis (MS), but no link was seen between a good diet and the risk of MS relapses or disability progression, a new study from Australia indicates. The study, “Higher…
July 31, 2023 News by Marisa Wexler, MS Relapses found to drive disability worsening in 1st years of MS In people with relapsing forms of multiple sclerosis (MS), relapses that occur in the first few years after the disease develops have a strong impact on rates of disability worsening ā but after about 2.5 years, more relapses don’t consistently result in a greater worsening of disability, according to…
July 10, 2023 News by Steve Bryson, PhD Mavenclad found comparable to Gilenya in highly active MS Mavenclad (cladribine) is equally as effective as Gilenya (fingolimod) in reducing relapse rates among multiple sclerosis (MS) patients with highly active disease, according to a new real-world comparison. Disability worsening and the development of new lesions also were similar between the two patient groups ā but…
July 6, 2023 News by Margarida Maia, PhD Kesimpta reduces relapses, brain lesions for up to 5 years: Study Up to five years of treatment with Kesimpta (ofatumumab) continues to keep the number of relapses and brain lesions low in people with relapsing forms of multiple sclerosis (MS), with most patients showing no evidence of disease activity. These are new data from the ongoing ALITHIOS study…
June 9, 2023 News by Lindsey Shapiro, PhD Ocrevus best to prevent MS relapses after stopping Tysabri: Study Ocrevus (ocrelizumab) ā given by infusion ā may work better than certain oral treatments to prevent relapses and disability worsening in people with relapsing-remitting multiple sclerosis (RRMS) who transition from Tysabri (natalizumab), a new study found. Individuals who switched to Ocrevus also were more likely to stay…
June 1, 2023 News by Margarida Maia, PhD Stress in MS linked to worse disability, more burden in US survey Being exposed to stress as children or adults makes it more likely that people with multiple sclerosis (MS) will experience more disability and/or a heavier burden from relapses, according to a new survey study of more than 700 people in the U.S. āMS is the leading cause of non-traumatic…
November 28, 2022 News by Marisa Wexler, MS Switching to Ocrevus Over Other MS Therapies Means Fewer Relapses People with relapsing-remitting multiple sclerosis (RRMS) whoĀ switch to Ocrevus (ocrelizumab) after discontinuing Gilenya (fingolimod) have fewer relapses than those who switch to Mavenclad (cladribine) orĀ Tysabri (natalizumab), according to a new study. Rates of disability worsening were similar for Ocrevus and Tysabri, but patients who switched…
November 4, 2022 News by Lindsey Shapiro, PhD #ECTRIMS2022 ā 3-year Data Show Evobrutinib Safely Lowers Relapses Long-term use of the investigational BTK inhibitor evobrutinib among people with relapsing forms of multiple sclerosis (MS) continues to maintain MS relapse rates, and keep MRI lesion activity low. That’s according to up to 3.5 years of data from a Phase 2 trial (NCT02975349) and its open-label…
October 28, 2022 News by Marta Figueiredo, PhD #ECTRIMS2022 ā Long-term Gilenya Reduces Pediatric Relapses Long-term treatment withĀ Gilenya (fingolimod) continues to be safe and lower the rate of relapses in children and adolescents with multiple sclerosis (MS) more than Avonex (interferon beta-1a) does. Thatās according to up to six years of data from the ongoing PARADIGMS Phase 3 trial (NCT01892722), wherein…
June 3, 2022 News by Patricia Inacio, PhD Study Ties Antinuclear AntibodiesĀ to Inflammation, Relapses The presence of self-reactive antibodies, typically seen in autoimmune diseases like scleroderma, may be common among patients with multiple sclerosis (MS). That finding from a small study indicates high levels of these antinuclear antibodies were correlated with relapse status and ongoing inflammation in MS. The study, āAntinuclear…
April 19, 2022 News by Lindsey Shapiro, PhD Long-term Gilenya Use Safe, Effective in Real-world Czech Study Treatment with Gilenya (fingolimod) for up to four years was found safe and lowered relapse rates among people with multiple sclerosis (MS) in the Czech Republic, according to a real-world study called GOLEMS. Older age, lower disability level, and fewer relapses prior to the treatment’s start were all…
January 21, 2019 Columns by Debi Wilson Recognizing Pseudo Exacerbations in MS My readers have recently brought something to my attention: They informed me that not all MS exacerbations (flare-ups, relapses, and attacks) are created equal. I have learned that along with the hardcore types, which usually require steroid treatment, there are also pseudo-exacerbations. I can always trace the causes of…
June 13, 2018 Columns by Cathy Chester Multiple Sclerosis, Comorbidities, and How to Live with Them Iām doing all I can to remain calm and keep stressors at bay all in the name of wellness. So Iām trying to meditate at least five minutes a day ā find a quiet room to sit tall, close my eyes, and focus on my…